120 completed, 56 terminated, 28 active not recruiting, 21 recruiting. 260 Phase 1, 89 Phase 2.
Follow Chronic Lymphocytic Leukemia: new trials by email Literature Review of Chronic Lymphocytic Leukemia trials Research Report on Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-11-02 |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-11-03 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies LMY-922 - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | Luminary Therapeutics | 27 | 2026-09-01 | 2026-07-01 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Mosunetuzumab for CLL MRD Clearance Mosunetuzumab, Ibrutinib, Acalabrutinib - Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Inhye Ahn | 40 | 2025-11-24 | 2025-12-15 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
| A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Obinutuzumab, ABBV-453 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | AbbVie | 4 | 2025-01-27 | 2026-09-11 |
| A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Sonrotoclax, Zanubrutinib - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 258 | 2025-01-23 | 2026-10-26 |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
| Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Zanubrutinib, Lenalidomide, Obinutuzumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2024-01-01 | 2024-08-09 |
| Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia Loncastuximab Tesirine and Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | University of Alabama at Birmingham | 24 | 2023-12-18 | 2026-10-20 |
| Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL Cyclophosphamide injection, Fludarabine Injection, CD19-CD34t metabolically programmed CAR transduced T-cells - B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 27 | 2023-11-06 | 2026-03-27 |
| A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . TQB3909 tablet - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 107 | 2023-10-11 | 2023-10-23 |
| Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 27 | 2023-10-02 | 2025-11-06 |
| Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies Anti-CD19 and anti-CD20 bicistronic CAR T- cells, Cyclophosphamide, Fludarabine - Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 58 | 2023-08-28 | 2026-10-16 |
| Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies CC312 - Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia | Phase 1 | Recruiting | CytoCares Inc | 44 | 2023-08-07 | 2025-09-22 |
| AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma Docirbrutinib - B-cell Malignancy, Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Carna Biosciences, Inc. | 120 | 2023-08-01 | 2025-12-10 |
| Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) SC291 - Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | Sana Biotechnology | 16 | 2023-05-02 | 2025-10-02 |
Showing 20 of 260. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (260) · Lymphoma, Non-Hodgkin (85) · Lymphoma, Mantle-Cell (48) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (47) · Leukemia (43) · Lymphoma, Follicular (38) · Lymphoma, Large B-Cell, Diffuse (38) · Lymphoma (33) · Lymphoma, B-Cell, Marginal Zone (33) · Leukemia, Myeloid, Acute (30) · Recurrence (27) · Lymphoma, B-Cell (26) · Neoplasms (25) · Waldenstrom Macroglobulinemia (23) · Multiple Myeloma (22)
Chronic Disease (260) · Disease Attributes (260) · Hemic and Lymphatic Diseases (260) · Pathologic Processes (260) · Pathological Conditions, Signs and Symptoms (260) · Hematologic Diseases (259) · Immunoproliferative Disorders (259) · Lymphatic Diseases (259) · Neoplasms by Histologic Type (259) · Lymphoproliferative Disorders (258) · Leukemia, Lymphoid (257) · Immune System Diseases (256) · Leukemia, B-Cell (252) · Neoplasms (235) · Leukemia (217)
Rituximab (39) · Cyclophosphamide (26) · fludarabine (26) · ibrutinib (20) · Lenalidomide (19) · venetoclax (19) · Bendamustine Hydrochloride (18) · fludarabine phosphate (16) · obinutuzumab (15) · acalabrutinib (11) · ublituximab (7) · Antilymphocyte Serum (6) · Interleukin-2 (6) · umbralisib (6) · duvelisib (5)
National Cancer Institute (NCI) (13) · Dana-Farber Cancer Institute (10) · M.D. Anderson Cancer Center (10) · Gilead Sciences (8) · TG Therapeutics, Inc. (8) · AbbVie (7) · University of Pennsylvania (5) · Acerta Pharma BV (4) · Novartis Pharmaceuticals (4) · University of California, San Diego (4) · Baylor College of Medicine (3) · Biogen (3) · Bristol-Myers Squibb (3) · Celgene (3) · City of Hope Medical Center (3)
United States (204) · China (21) · Australia (18) · France (18) · Germany (18) · United Kingdom (16) · Spain (15) · Italy (14) · Canada (11) · South Korea (10) · Poland (9) · Belgium (7) · Israel (7) · Netherlands (7) · Japan (5)
Michael Choi, MD (3) · Benjamin Tomlinson, MD (2) · Catherine J. Wu, MD (2) · Helen Heslop, MD (2) · James N Kochenderfer, M.D. (2) · Januario Castro, M.D. (2) · Jennifer Brown, MD, PhD (2)
PMID 34398557, PMID 34515338, PMID 20882050, PMID 24782509, PMID 29296805, PMID 31023700, PMID 31723767, PMID 34608724, PMID 16186597, PMID 18003886, PMID 18418404, PMID 18824593, PMID 18931344, PMID 19225537, PMID 19238148, PMID 19843887, PMID 19965642, PMID 20408846, PMID 20595516, PMID 20661232, PMID 21816833, PMID 22009536, PMID 22184378, PMID 22289893, PMID 23435461, PMID 23524863, PMID 23645694, PMID 23810788, PMID 23912587, PMID 24443277, PMID 24615776, PMID 24615777, PMID 24615778, PMID 24777753, PMID 25082342, PMID 25145344, PMID 25217392, PMID 25301708, PMID 25925619, PMID 26472751, PMID 26639348, PMID 26641137, PMID 26643449, PMID 27391907, PMID 27400247, PMID 27862308, PMID 27881039, PMID 28054442, PMID 28089635, PMID 28314788
2014 (3), 2016 (3), P30CA016058 (3), P30CA033572 (3), U01CA076576 (3), 2015 (2), 2019 (2), 2023 (2), P30CA016672 (2), 2009 (1), 2018 (1), N01CM00070 (1), N01CM62207 (1), P30CA008748 (1), P30CA015704 (1)